BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26384240)

  • 1. Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
    Ravandi F; Kantarjian H
    Lancet Oncol; 2015 Oct; 16(13):1274-5. PubMed ID: 26384240
    [No Abstract]   [Full Text] [Related]  

  • 2. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATRA plus arsenic gets another "A" in APL.
    Park JH
    Blood; 2012 Aug; 120(8):1535-6. PubMed ID: 22918418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.
    Young CS; Clarke KM; Mills KI
    EBioMedicine; 2015 Jun; 2(6):487-8. PubMed ID: 26288810
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acute promyelocytic leukemia.
    Miura Y; Suyama K; Takano T
    N Engl J Med; 2013 Oct; 369(15):1471-2. PubMed ID: 24106949
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of acute promyelocytic leukemia.
    Lo-Coco F; Orlando SM; Platzbecker U
    N Engl J Med; 2013 Oct; 369(15):1472. PubMed ID: 24106948
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting agents alone to cure acute promyelocytic leukemia.
    Chen SJ; Chen Z
    N Engl J Med; 2013 Jul; 369(2):186-7. PubMed ID: 23841735
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy-free treatment of acute promyelocytic leukemia.
    Ravandi F
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):498-500. PubMed ID: 26351810
    [No Abstract]   [Full Text] [Related]  

  • 9. How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
    Koehler M; Fischer T
    J Clin Oncol; 2015 Mar; 33(9):1090-1. PubMed ID: 25691667
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to M. Koehler et al.
    Efficace F; Cottone F; Lo-Coco F
    J Clin Oncol; 2015 Mar; 33(9):1091-2. PubMed ID: 25691680
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
    Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
    Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
    [No Abstract]   [Full Text] [Related]  

  • 12. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
    Estey EH; Hutchinson F
    J Clin Oncol; 2011 Jul; 29(20):2743-6. PubMed ID: 21646610
    [No Abstract]   [Full Text] [Related]  

  • 13. [Arsenic treatment for leukemia: new model of human cancer target treatment].
    Zhao WW; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance to therapy in acute promyelocytic leukemia.
    Lehmann-Che J; Bally C; de Thé H
    N Engl J Med; 2014 Sep; 371(12):1170-2. PubMed ID: 25229938
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia].
    Guan W; Li WJ; Yang L; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):353-357. PubMed ID: 28446274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.